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Abstract  
A randomized, controlled clinical trial established the efficacy and safety of short-term 
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use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of 
long-term hydroxyurea usage, patients in this trial were followed for 17.5 years during 
which they could start or stop hydroxyurea. The purpose of this follow-up was to search 
for adverse outcomes and estimate mortality. For each outcome and for mortality, exact 
95% confidence intervals were calculated, or tests were conducted at α = 0.05 level (p-
value <0.05 for statistical significance). Although the death rate in the overall study 
cohort was high (43.1%; 4.4 per 100 person-years), mortality was reduced in individuals 
with long-term exposure to hydroxyurea. Survival curves demonstrated a significant 
reduction in deaths with long-term exposure. Twenty-four percent of deaths were due to 
pulmonary complications; 87.1% occurred in patients who never took hydroxyurea or 
took it for <5 years. Stroke, organ dysfunction, infection and malignancy were similar in 
all groups.  Our results, while no longer the product of a randomized study because of 
the ethical concerns of withholding an efficacious treatment, suggest  that long-term use 
of hydroxyurea in adults is safe and might decrease mortality. 
 
Introduction 
Hydroxyurea was introduced as a treatment for sickle cell anemia (homozygosity 
for HBB glu6val) more than 25 years ago based on its ability to increase fetal 
hemoglobin (HbF) level.[1] In a randomized, controlled trial in adults (the Multicenter 
Study of Hydroxyurea in Sickle Cell Anemia or MSH) , hydroxyurea was associated with 
a reduction in acute painful episodes and acute chest syndrome events, and HbF levels 
increased.[2-4] Observational studies in children suggested that hydroxyurea was safe 
and beneficial.[5]  Because of the concern that hydroxyurea, a cell cycle-specific agent, 
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might cause longer-term adverse effects [6], MSH patients were followed after the 
controlled trial ended. Although patients were followed prospectively using a 
predetermined protocol, ethical tenets required that treatment no longer be randomized. 
Therefore, hydroxyurea was used according to patient and physician discretion and all 
subsequent results must be interpreted with this caveat. After 9 years of follow-up, we 
found that mortality was related to HbF concentration and the rate of acute painful 
episodes and acute chest syndrome, and neither untoward reproductive outcomes nor 
an increased incidence of neoplasia were observed. Analysis of this first follow-up 
interval suggested that patients who took hydroxyurea for at least 1 year had a 40% 
reduction in mortality.[7]  
To further examine the risks and benefits of  long-term hydroxyurea we extended 
follow-up of MSH patients to 17.5  years. This second follow-up protocol was different 
and its focus was to; identify serious complications of treatment, detect organ 
dysfunction, assess all cause mortality, and classify causes of death. As in the initial 9 
year follow-up, patients were no longer randomized and most, but not all patients 
elected to either continue hydroxyurea at doses recommended by their treating 
physicians, or to start hydroxyurea anew. Laboratory tests were done for clinical 
purposes and were not required for the extended follow-up.  Because of this design, our 
observational study cannot provide the same strength of evidence for harm or benefit as 
would a randomized, controlled trial with a single well-defined outcome measure. 
Nevertheless, it can screen for findings that might warrant further investigation. Our 
results are consistent with the initial post-randomization follow-up interval and continue 
to suggest  that long-term use of hydroxyurea is safe and might reduce mortality.  
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Methods 
The objective of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia 
(MSH) Patients' Follow-Up was to determine whether there were long-term adverse 
outcomes of treatment of sickle cell anemia with hydroxyurea occurring between the 
date patients were enrolled in the MSH clinical trial and end of the patient follow-up 
(August 27, 2009). Patients were seen annually when data on hydroxyurea use and 
reportable events were collected.[7] Although this observational study was prospective 
in nature, hydroxyurea use and clinical events were determined retrospectively on an 
annual basis. The retrospective nature of this data makes the determination of actual 
hydroxyurea dose less reliable than assessment of monthly drug use. 
Exploratory statistical methods were used to screen a large number of potential 
adverse outcomes. For each outcome, exact 95% confidence intervals were calculated, 
or tests were conducted at α = 0.05 level (p-value <0.05 for statistical significance). 
Significant findings should only be regarded as indicators of association. Therefore, this 
study will not provide the same strength of evidence for harm or benefit as would be 
obtained from a randomized trial with a single well-defined outcome measure, but can 
screen for findings that might warrant further investigation.   
Patients were enrolled in the MSH clinical trial at an approximately uniform rate 
over the course of 15 months, and were followed in the MSH Patients' Follow-Up to a 
common closing date. Thus, even if there were no patients lost to observation (e.g., 
through death) for some outcomes, follow-up times would be unequal.  For this reason, 
event rates are reported as “number per 100 person-years.” Two-sided exact 95% 
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confidence limits were calculated when one or more occurrences of a given type of 
event were observed. If no occurrences were observed, a one-sided exact 95% 
confidence limit was calculated. Exact 95% confidence intervals for the difference 
between event rates were used to perform pair-wise comparisons between the “a priori” 
cumulative hydroxyurea exposure groups (two-sided). 
The Product-Limit (Kaplan-Meier) method [8] was used to examine the 
relationship between cumulative hydroxyurea usage throughout the course of the 
patient’s involvement with the clinical trial and the patient follow-up study with mortality. 
The following tests were used to detect differences in mortality between the various 
cumulative hydroxyurea usage categories: The log-rank, Gehan-Breslow Generalized 
Wilcoxon, and Tarone-Ware tests. The log-rank test is sensitive to differences in the 
right tails of survival distributions (i.e., at later times), the Gehan-Breslow Generalized 
Wilcoxon test gives more weight to earlier failures (deaths), and the Tarone-Ware test 
falls in between.[9-14] 
The Kruskal-Wallis test [15] was used to compare the baseline categorical 
distributions of the patients who were in each of the cumulative hydroxyurea exposure 
categories considered in our analysis. Analysis of variance was used to compare 
continuous measurements. The cumulative hydroxyurea use categories are based on 
each patient’s known cumulative exposure to hydroxyurea from enrollment in the MSH 
clinical trial and throughout the entire MSH Patients' Follow-Up. The following “a priori” 
defined cumulative hydroxyurea exposure categories were used: never (zero years of 
cumulative exposure); years<5 (denoted as <5 years); 5≤years<10 (denoted as 5-10 
years); 10≤ years<15 (denoted as 10-15 years; years ≥15 (denoted as  ≥15 years). 
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These studies were approved by the Institutional Review Boards of all 
participating institutions. 
 
Results 
The MSH patients were followed for 17 years and 7 months (January 28, 1992 
through August 27, 2009). Two hundred ninety-nine patients made up the original MSH 
study population. Table I presents the characteristics of the patients at baseline 
according to cumulative hydroxyurea exposure at the end of follow-up. No significant 
differences were present in baseline data when patients were grouped by cumulative 
hydroxyurea exposure.  No significant difference in baseline age was found among 
cumulative hydroxyurea exposure groups (p=0.48) suggesting that the reduction in 
mortality found in the long-term cumulative hydroxyurea exposure categories is not an 
effect of age. 
Table IIA shows that overall, 43.1% of the original MSH cohort has died 
(129/299). This corresponds to a rate of 4.4 per 100 person-years. Also shown in Table 
IIA is the cumulative event rates for the 17.5 years MSH experience. There were 14 
patients who had at least one reported incident of a stroke (a cumulative total of 18 
episodes; 6.0%; a rate of 0.6 per 100 person-years); 16 patients with renal dysfunction 
(17.4%; a rate of 1.8 per 100 person-years); 7 patients with  hepatic dysfunction (6.0%; 
a rate of 0.6 per 100 person-years); 3 patients who had a reported malignancy (1.0%; a 
rate of 0.1 per 100 person-years); and 23 patients who had at least one reported 
incident of  sepsis/infection (18.4%; a rate of 1.9 per 100 person-years). Of the 3 
patients with malignancies, 1 woman died due to metastatic cancer (uterine cancer: 
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malignant mixed Müllerian tumor). She was in the 5-10 cumulative hydroxyurea 
exposure category. Another woman was diagnosed with breast cancer (she was in the 
<5 years cumulative hydroxyurea exposure category) and a third woman was diagnosed 
with metastatic adenocarcinoma, primary unknown (she was in the 5-10 years  
cumulative hydroxyurea exposure category). 
The exact 95% confidence interval for mortality and morbidity by years of 
cumulative hydroxyurea exposure are shown in Table IIB. The exact 95% confidence 
intervals for the difference between event rates ( 3 pair-wise comparisons) indicated 
possible evidence for reduced mortality when long-term exposure to hydroxyurea 
occurred.  
Figure 1 illustrates the cumulative mortality for the MSH patients with respect to 
the “a priori” defined cumulative hydroxyurea exposure categories. The tests used to 
detect differences in mortality between the various cumulative hydroxyurea usage 
categories (the log-rank, Gehan-Breslow Generalized Wilcoxon, and Tarone-Ware 
tests) all had a p-value<.0001 providing additional evidence for a possible reduction in 
mortality with long-term exposure to hydroxyurea. 
Cause of death was also assessed with respect to cumulative hydroxyurea 
exposure (Table III). There were no reported deaths for the group of patients who had a 
cumulative hydroxyurea exposure of ≥15 years. Twenty-four percent (31/129) of the 
deaths were due to pulmonary complications. The majority (87.1%) of these 31 deaths 
occurred in patients never exposed to hydroxyurea and with <5 years exposure. Only 2 
deaths due to pulmonary complications occurred in the patient group that had a 
cumulative hydroxyurea exposure of 5-10 years, 2 deaths occurred in the group 10-15 
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years, and none occurred in the group years ≥15 years. Twenty-five (19.4%) of the 
reported deaths were not classified because they were determined with the use of the 
Social Security Death Index (SSDI) that does not provide a cause of death.  
 
Discussion 
 A consensus exists that hydroxyurea should be more widely used.[16, 17] 
Our follow-up of more than  17 years provides additional evidence that in adults with 
sickle cell anemia, where treatment is started in the 4th decade of life, this drug is safe 
and its use also appears to be associated with reduced mortality. (Figure 1, Table III)  
Supporting these observations,  in 330 Greeks with sickle cell disease, predominantly 
HbS-β+ and HbS-β0 thalassemia (less than 20% of treated patients had sickle cell 
anemia), 131 received hydroxyurea, based on the severity of symptoms of disease.[18] 
Treated patients were compared with less symptomatic cases and were followed for a 
median time of 8 years, compared with 5 years for untreated patients. Along with a 
reduction of the incidence of painful episodes, blood transfusion, hospitalizations, and 
incidence of acute chest syndrome, the probability of 10 year survival was 86% in 
treated cases compared with  65% in those not treated.  As in our study, hydroxyurea 
treatment was safe.  
 The long-term effects of hydroxyurea started early in life on morbidity and 
mortality is a question unlikely to ever be answered by a randomized controlled trial. It is 
therefore critical to examine our results and the results of other observational trials 
given the limitations of the study design; some shortcomings of the MSH trial and follow-
up have already been discussed.[7, 19] MSH results might not apply to patients with 
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different constellations of symptoms, different ages and individuals with HbSC disease. 
In the follow-up study, comparisons of patients were no longer randomized so patients 
who might receive more medical care while taking hydroxyurea might have lived longer 
for reasons other than their hydroxyurea treatment. MSH patients were adults with 
frequent painful episodes, which are one predictor of mortality; as the study progressed, 
patient numbers fell due to death and losses to follow-up.[20] The 69 (23.1%) patients 
lost to follow-up after 17.5 years were still alive, however their updated hydroxyurea 
usage data, clinical outcomes and reproductive events were not available. Cumulative 
hydroxyurea exposure was reported as a range of years because for many study 
participants some hydroxyurea use was not always reported. Also, hydroxyurea use 
was often intermittent. Laboratory data were not collected according to protocol so HbF 
level and mean corpuscular volume cannot be used to gauge compliance with 
treatment. Notwithstanding these caveats, our observational data provides a "real 
world" understanding of long-term hydroxyurea exposure, albeit in patients who initially 
volunteered for a controlled clinical trial.  It also speaks to effectiveness and safety since 
the conditions of a randomized clinical trial seldom reflect clinical practice.  
The cumulative hydroxyurea exposure for each patient is an accurate minimum 
exposure. For example, a patient with "≥15 years" has at least 15 years total drug 
exposure while one with "10-15" has at least 10 years total exposure (Tables II, III). 
Thus, reasonable conclusions can be drawn regarding long-term hydroxyurea exposure. 
Short-term and mid-term "cumulative hydroxyurea exposure" groups could have a 
maximum exposure greater than that defined. For example, a patient with "5-10 years" 
has an accurate minimum of 5 years but the maximum could be 10 years or greater. 
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Cumulative hydroxyurea exposure categories "never', "<5 years", and "5-10 years have 
been discussed.[7] 
 In all MSH studies, teratogenic changes were not present in the pregnancies that 
resulted in live births regardless of whether the mother or the father was treated.[21] 
Among newborns there were no developmental delays up to age 36 months.[20]  Of 22 
offspring of study participants (a subset of the known MSH offspring), aged from 6 
months to 17 years, Vineland Adaptive Behavior Scales  showed that they were 
functioning in the average range of development. Since all offspring were not studied 
the these results are not definitive.[22] 
After 17.5 years of follow-up, hydroxyurea was associated with improved survival 
without accompanying serious adverse events. Importantly, there was no indication that 
the incidence of serious complications like stroke, infections or neoplasia were 
increased by exposure to this drug (Table II). The absence of serious complications 
coupled with the suggestion that mortality was reduced raises the question of whether 
the indications for treatment of adults with sickle cell anemia should be expanded to 
include individuals without frequent vasoocclusive events. For example, patients with 
rare painful episodes but other complications like priapism [23], liver disease [24], 
proteinuria [25], severe chronic anemia associated with mild azotemia [26], or 
pulmonary hypertension [27] could be reasonable candidates for long-term hydroxyurea 
treatment.  The intensity of hemolysis might contribute to sickle vasculopathy and is 
associated with these disease complications and with survival.[28, 29]  As one example 
of the often silent but inexorable progression of sickle vasculopathy, pulmonary 
hypertension is usually not clinically evident but is a major risk factor for mortality.[30-
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32] In the Greek study, a fall in serum LDH level―a reasonable marker of intravascular 
hemolysis―in response to hydroxyurea, along with HbF were the best predictors of 
survival.  
HbF levels are associated with decreased morbidity and mortality in sickle cell 
anemia and sufficiently high concentrations of HbF evenly distributed among sickle 
erythrocytes can totally abrogate the disease pathophysiology.[20, 33, 35] Agents that 
stimulate higher HbF levels, might alter the fundamental course of disease by inhibiting 
HbS polymerization and its untoward effects. In hydroxyurea-treated patients, as HbF 
increases, hemolysis is usually reduced, as reflected by an increased hemoglobin 
concentration with reduced bilirubin level and reticulocyte count.[2, 3, 36] Although 
some questions remain about the ameliorative effect of HbF on some disease events 
[30-32, 37] and if  increased HbF is the only beneficial effect of hydroxyurea.[38-41], 
with early treatment, certain features of sickle vasculopathy might be reversible.[42-44]  
If sufficiently high levels of HbF can be induced in most erythrocytes early in life, the 
progression of sickle vasculopathy and its associated morbidity and mortality might be 
forestalled.  
A randomized, double-blind placebo controlled trial of hydroxyurea in unselected 
babies with sickle cell anemia has been completed (Clinical Trials.gov; NCT 
00006400).[45] Preliminary analysis showed that the hematological changes and clinical 
results were very closely aligned with those of hydroxyurea-treated MSH 
patients.(Wong, W,  4th Annual Sickle Cell Disease Research and Education 
Symposium, Feb 14-19, 2010, Hollywood FL) Although these and other short term 
studies have a very favorable safety profile, the  intermediate and long-term adverse 
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effects of hydroxyurea given to young patients and continued for decades remains to be 
determined. 
Untreated sickle cell anemia is a lethal disease with a high mortality rate, 
especially in patients with frequent vasculopathic and vasoocclusive events. Even with  
so-called “mild disease,” it is the rare patient that escapes these complications.[29, 33, 
47] Besides drug therapy, transfusions and stem cell transplantation can be efficacious 
but each has complications.[48] Severely affected adult patients in the fourth decade of 
life, like those enrolled in the MSH and in the Greek trial, are arguably the least likely 
group of individuals to benefit from hydroxyurea or any drug whose mechanism of 
action is to induce higher levels of HbF. Nevertheless, in the MSH follow-up, over 17.5 
years of observation, individuals with the greatest exposure to the drug appeared to 
have improved survival raising the question of whether the indications for this drug 
should be expanded. The relentless progression of vasculopathic complications of 
disease, suggest that most adult patients with sickle cell anemia and HbS-β0 
thalassemia could be treated with hydroxyurea with likely benefit while pediatric studies 
to date strongly argue for beginning this drug even earlier in life before the development 
of irreversible vasculopathy and organ damage.   
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Table and Figure Legends 
Table  I: Characteristics of the Patients at Base Line, According to Cumulative 
Hydroxyurea Exposure. Baseline rows show values obtained prior to randomization to receive 
hydroxyurea or a placebo. Columns shw the cumulative hydroxyurea use. 
Table II: Cumulative Event Rates during the MSH Trial and Follow-Up by Cumulative 
Hydroxyurea Exposure. 
(A) The first column shows death and events by total enrollment in the MSH trial, column 2 
shows death and events by patients randomized to hydroxyurea (HU) during the MSH trial, and  
column 3 shows death and events by patients randomized to placebo (PL) during the MSH trial. 
The remaining columns consider the ‘a priori’ defined cumulative hydroxyurea exposure 
categories. 
(B) Event Rates per 100 Person-years (Exact 95% confidence limits for events; n per 100 
person-years) 
Table III. Cause of Death According to Cumulative Hydroxyurea Exposure. (129 deaths) 
Figure 1. Cumulative Mortality During the MSH Follow-Up by Cumulative Hydroxyurea 
Exposure. 
